	KOPRAN LIMITED	
STATEMENT OF CONSOLIDATED AND STANDALONE	UNAUDITED FINANCIAL RESULTS FOR QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2019	

1 1		Consolidated St						andalone					
Particulars	For t	he Quarter e	ended	Half Yea	r ended	For the year ended	For the Quarter ended			Half Year ended		For t year er	
1	30-09-2019	30-06-2019	30-09-2018	30-09-2019	30-09-2018	31-03-2019	30-09-2019	30-06-2019	30-09-2018	30-09-2019	30-09-2018	31-0	
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited		Unaudited			Unaudited	Au	
(1) Revenue from Operations	8,778.18	8,414.90	9,215.27	17,193.08	15,270.10	35,790.10	4,828.46	3,774.24	4,900.57	8,602.70	7,668.63	19	
(2) Other Income	23.74	13.25	28.10	36.99	176.02	294.84	46.71	49.71	62.46	96.42	161.65	l I	
(3) Foreign exchange Gain	120.07	234.29	-	354.36	-	11.05	113.15	143.22	-	256.37	-	l i	
(4) Total Income (1+2+3)	8,921.99	8,662.44	9,243.37	17,584.43	15,446.12	36,095.99	4,988.32	3,967.17	4,963.03	8,955.49	7,830.28	1	
(5) Expenses									1				
(a) Cost of materials consumed	5,540.20	5,723.10	4,315.11	11,263.30	8,591.63	19,618.95	2,426.48	2,383.91	2,436.71	4,810.39	3,910.71		
(b) Purchase of stock-in-trade	637.35	152.80	433.72	790.15	718.77	2,104.75		202.71	483.29	809.14	781.52		
(c) Changes in Inventories of finished goods, stock-in-trade	(887.40)		777.35	(1,522.53)	(523.59)	(926,71)		(322.32)	(72.23)	J	(291.70)	1	
and work-in-progress	()	()		(,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	(,	(,		(,		(,	(1	
(d) Employee benefits expense	916.80	961.53	856.55	1,878.33	1,730,46	3,710,61	520.36	528,26	479.39	1.048.62	947.05		
(e) Finance costs	196.65	209.39	279.19	406.04	439.75	899.06	124.74	133.64	145.62	258.38	240.18	1 '	
(f) Depreciation and amortisation expense	247.51	229,83	218.61	477.34	433.97	873.92		79.80	77.64	174.31	155.76	1	
(g) Other expenses	1,505.86	1,456.49	1,553.41	2,962.35	2,885.63	6,649,16	812.03	752.75	858.53	1,564.78	1.482.16		
(h) Foregin exchange Loss	1,000.00	1,400.49	271.95	2,302.35	488.90	0,045.10	012.03	152.75	190.58	1,004.70	339.56	i .	
Total Expenses (5)	8,156.97	8,098.01	8,705.89	16,254.98	400.90	32,929,74	4.643.82	3,758,75	4,599.53	8,402.57	7,565.24	1	
(6) Profit before exceptional items and tax (4-5)	765.02	<u>8,098.01</u> 564.43	537.48	1,329.45	680.60	32,929.74	4,643.82	208.42	4,599.53	<u>8,402.57</u> 552.92	265.04	_	
(7) Exceptional items (Net)	100.02	504,43	557.48	1,329.45	00.00	3,100,25	344.50	200.42	303.50	552.92	200.04		
(7) Exceptional items (Net) (8) Profit before tax (6-7)	765.02	564,43	537.48	1,329.45	680.60	3,166.25	344.50	208.42	363.50	552.92	265.04		
(9) Tax expense	765.02		037.40	1,329.45	600.60	3,100.25	344.50	208.42	363.50	552.92	265.04		
	450.05	440.50	5400		54.00							1	
(a) Current Tax	159.25	118.53	54.00	277.78	54.00	528.37	74.21	38.84	54.00	113.05	54.00	i	
(b) Deferred Tax	38.29	23.73	53.82	62.02	78.65	235.58	26.95	18.54	32.15	45.49	3.83	j	
(10) Profit for the period / Year (8 - 9)	567.48	422.17	429.66	989.65	547.95	2,402.30	243.34	151.04	277.35	394.38	207.21		
(11) Other Comprehensive Income (i) Items that will not be reclassified subsequently to profit or loss													
 Remeasurement of defined employee benefit plans [(expenses) / write back] 	(11.92)	(11.92)	(5.91)	(23.84)	(9.78)	(47.69)	(9.18)	(9.19)	(3.87)	(18.37)	(7.74)		
Income tax effect on Net changes in Fair value of investments in equity shares carried at fair value through OCI	2.55	2.56	1.08	5.11	2.16	10.23	2.55	2.56	1.08	5.11	2.16		
[credit / (charge)] b) Net changes in Fair value of investments in equity shares	-	-	0.53	.	(0.74)	(1.22)	(0.00)	-	(0.49)	(0.00)	(0.74)		
carried at fair value through OCI [(expenses) / income]]									
Income tax effect on Remeasurement of defined employee benefit plans [(charge) / credit]	-	-	0.21	-	0.21	0.07	-	-	-	-	0.21		
ii) a) Items that will be reclassified to profit or loss Exchange difference in translating the financial statement	- 3.88	-	-	3.88	-	13.06		-	-	-	-		
of foreign operation b) Income tax relating to items that will be reclassified to profit or loss	-	-	-		-	-	-	-	-	-	-		
Total Other Comprehensive Loss for the period / year (11)	(5.49)	(9.36)	(4.09)	(14.85)	(8.15)	(25.55)	(6.63)	(6.63)	(3.28)	(13.26)	(6.11)		
(12) Total Comprehensive Income for the period / year (10+11)	561.99	412.81	425.57	974.80	539.80	2,376.75	236.71	144.41	274.07	381.12	201.10		
(13) Paid-up Equity Share Capital (Face value Rs. 10/- each) (14) Earnings Per Share (EPS) (Fa <u>ce</u> value Rs. 10/- each)	4,325.00	4,325.00	4,325.00	4,325.00	4,325.00	4,325.00	4,325.00	4,325.00	4,325.00	4,325.00	4,325.00	- <u></u> -	
Colling Cop RAN	1.31 1.31	0.95 0.95	0.99 0.99	2.29 2.29	1.27 1.27	5.55 5.55		0.33 0.33	0.64 0.64	0.91 0.91	0.48 0.48		

ACO OT B. TT

* KHAN

ERET: N

Notes:-

1) The Statement of consolidated and standalone financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act 2013, read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015, Companies (Indian Accounting standards) (Amendment) Rules, 2016 and other accounting principles generally accepted in India. There is no minority interest.

2) The above consolidated and standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on October 24, 2019 and have been subjected to limited review by the Statutory Auditors of the Company.

3) The consolidated and standalone statement of cash flow for the half year ended September 30, 2018 as reported in these financial results have been approved by the Company's Board of Directors, but have not been subjected review / audit by the auditors.

4) The Company is engaged primarily in the Pharmaceuticals business and there are no separate reportable segments as per Ind AS 108 on " Operating Segment Reporting".

5) Effective April 01, 2019, the Company has adopted Ind AS 116 Leases and reviewed all contracts having lease components existing on April 01, 2019. These contracts are in the nature of short-term leases and hence there is no impact of application of Ind AS 116 on the financial results of the Company.

6) Duirng the period, the subsidiary Korpan Research Laboratories Limited has invested GBP 10000 in Kopran (UK) Ltd. and has become wholly owned subsidiary company of Kopran Research Laboratories Limited.

7) Figures for the previous period have been regrouped or reclassified, wherever necessary to make them comparable with the figures of the current period.



Place : Mumbai Date : 24th October,2019



	(Rs. in L Consolidated Standalone					
				lalone		
Particulars	As at	As at	As at	As at		
	30-09-2019 Unaudited	31-03-2019 Audited	30-09-2019 Unaudited	31-03-201 Audited		
ASSETS	Unaudited	Audited	Unaudited	Audited		
Non-current assets						
Property, Plant and Equipment	11,180.93	11,238.32	4,229.56	4,178.8		
Capital work-in-progress	1,898.81	1,714.41	93.70	93.7		
Goodwill	0.58	0.58	-			
Other Intangible Assets	20.33	23.28	8.08	9.5		
Intangible assets under development	731.99	714.96	598.25	581.6		
Financial Assets						
Investments	2.30	2.30	15,782.86	15,751.6		
Loans receivables	356.41	191.68	288.93	131.8		
Deferred tax assets (net)	254.87	295.25	254.87	295.2		
Other non-current assets	639.93	293.83	56.38	71.3		
fotal Non-current assets	15,086.15	14,474.61	21,312.63	21,113.7		
. Current assets						
Inventories	8,376.02	7,344.62	2,873.02	2,518.9		
Financial Assets						
Trade receivables	7,854.77	8,664.35	4,150.40	4,459.0		
Cash and cash equivalents	122.91	41.47	20.15	20.		
Bank Balances other than cash and cash equivalents above	360.18	354.48	85.00	84.4		
Loans receivables	111.01	445.05	79.07	535.9		
Other financial assets	309.90	429.56	280.35	390.7		
Other Current Assets	3,919.26	3,477.17	3,109.32	2,732.8		
Total Current Assets	21,054.05	20,756.70	10,597.31	10,742.		
otal Assets	36,140.20	35,231.31	31,909.94	31,856.2		
EQUITY AND LIABILITIES Equity Equity Share Capital	4,324.89	4,324.89	4,324.89	4,324.8		
Other Equity	13,497.48	12,522.68	17,900.41	17,519.2		
Total Equity	17,822.37	16,847.57	22,225.30	21,844.		
iabilities						
I. Non-current liabilities	j					
Financial liabilities						
Borrowings	3,211.45	4,111.90	1,366.22	2,170.9		
Provisions	672.29	641.58	391.19	360.4		
Deferred tax liabilities (net)	210.16	158.96				
Total Non-Current Liabilities	4,093.90	4,912.44	1,757.41	2,531.4		
2. Current Liabilities	1					
Financial Liabilities	5 500 40	4 5 4 4 4 9	0 700 04	4 000 /		
Borrowings	5,522.18	4,544.42	2,793.34	1,883.2		
Trade payables	444.00	440.40	400.04	440		
a) total outstanding dues of micro enterprises and small	141.29	116.43	133.31	116.4		
enterprises		4 000 17	0 470 07	0 407 /		
b) total outstanding dues of creditors other than micro	5,482.86	4,999.47	3,173.07	3,127.6		
enterprises and small enterprises	0.004.00	0.000.40	4 450 00	4		
Other Financial Liabilities	2,091.68	2,666.43	1,459.68	1,742.4		
Other current liabilities	639.83	857.84	260.84	510.2		
Provisions	94.46	71.47	66.26	66.2		
Current tax liabilities (Net)	251.63	215.24	40.73	34.4		
otal Equity and Liabilities	14,223.93	13,471.30	7,927.23	7,480.6		
viai Lyuky aliu Liabilikes	36,140.20	35,231.31	31,909.94	31,856.3		
QRAN WUM 400 0	115/148					
(*\	1.11	Surendra So				
ace : Mumbai te : 24th October,2019	/ & //	Splennia -				

KOPRAN LIMITED

8) Consolidated / Standalone Statement of Assets and Liabilities:

、

.

DELWAL MUMBA 4000

9) STANDALONE STATEMENT OF CASH FLOWS	FOR THE	HALF YEAR END		0, 2019 (Rs. in Lakh:	
Particulars		Half Year Ended September 30, 2019	Half Year Ended September 30, 2018	As at March 31, 2019	
		Unaudited	Unaudited	Audited	
Cash flow from operating activities					
Net Profit before tax		552.92	265.04	1,735.7	
Adjustments for:		174.31	155.76	310.6	
Dividend income		(0.01)	155.70	(0.0	
Finance cost		258.38		545.5	
nterest income		(4.92)	(2.78)	(16.8	
Profit on sale of Investment		-		-	
Inrealised foreign exchange (gain) / loss (net)		(79.15)	(329.53)	(386.8	
Provision / write off for expected credit loss / trade			(3.42)		
eceivables / advances (net)		12.70	(50.00)	29.2	
iabilities written back (net)		(0.24) (31.25)	(56.89) (31.25)	(87.0)	
inancial guarantee Income		882.74	237.12	2,067.8	
Increase) / Decrease in inventories		(354.09)	(655.13)	456.5	
Decrease / (increase) in trade receivables		240.40	(84.42)	-2485.1	
Decrease / (increase) in Loans receivables		199.62	(8.54)	48.7	
ncrease in other current / non-current assets		(376.55)	597.03	588.2	
ncrease / (Decrease) in trade payables		64.84	716.31	443	
Decrease) / Increase in provision for retirement benefits		12.34	23.15	47.7	
Decrease) / Increase in other financial liabilities		35.70		108.6	
Decrease) / Increase in other current liabilities		(249.41) 455.59	(0.10)	<u> </u>	
Direct taxes paid (Net of refunds)		(106.73)	(140.77)	-393.6	
Net cash flow from operating activities	(A)	348.86	1,048.77	1,183.7	
Cash flow (used in) / from investing activities Purchase of fixed assets, including capital work-in-progress		(223.58)	(106.26)	(256.9	
Purchase of intangibles including Intangible assets under levelopment		(16.62)	(47.78)	(326.8	
Proceeds from sale of fixed assets		-	8.73	8.7	
Decrease in Creditors for capital goods		(13.44)	(38.32)	(23.6	
Decrease / (increase) in Capital Advance Proceeds from Non - current investments		15.02	26.60	<u>(17.6</u>	
Bank Balances Other than Cash and Cash Equivalents		(0.55)	41.72	<u>1.4</u> 41.4	
Decrease in other financial assets		236.89	234.83	209.4	
Decrease / (increase) in Loans receivables		100.14	(758.82)	(100.1	
nterest Income		4.92	2.78	16.8	
Dividend Income		0.01	-	0.0	
Net cash flow used in investing activities	(B)	102.79	-636.52	-447.3	
Cash flow (used in) / from financing activities					
Repayment of long-term borrowings (Net)		(6.74)	(4.42)	-9.0	
Redemption of 10% Non Convertible Non Cumulative Redeemable Preference Shares of Rs. 10 each		(858.00)			
Proceeds from / (Repayment) of Inter corporate deposits					
		(240.00)	524.41	290.8	
Proceeds from / Repayment of short-term borrowings (Net)		915.81	(672.13)	-463	
Current Maturites of Long term debts		15.49	(5.48)	-21.5	
nterest accrued		(20.27)	(14.49)	5.7	
nterest paid		(258.38)	-240.19	-545.5	
Net cash flow (used in) / from financing activities	(C)	-452.09	-412.30	-742.7	
let increase in cash and cash equivalents	(A+B+C)	(0.44)	(0.05)	(6.3	
Cash and cash equivalents at the beginning of the year Period		20.59	26.94	26.9	
ffect of exchange rate changes on Cash and cash quivalents					
Cash and cash equivalents at the end of the year /		20.15	26.89	20.5	

RA 400 018. FOR KOPRAN LINITED MITES C Surendra Somani Executive Vice Chairman RLI

•

•

•

•

٠

۲

Place : Mumbai Date : 24th October,2019



Cash flow from operating activities Net Profit before tax Adjustments for: Depreciation and Amortisation Expense Amortisation of premium on operating lease Dividend income Finance cost Interest income Profit on sale of Investment Unrealised foreign exchange (gain) / loss (net)		2019 Unaudited 1,329.45	2018 Unaudited	2019
Net Profit before tax Adjustments for: Depreciation and Amortisation Expense Amortisation of premium on operating lease Dividend income Finance cost Interest income Profit on sale of Investment Unrealised foreign exchange (gain) / loss (net)		1 320 45		Audited
Adjustments for: Depreciation and Amortisation Expense Amortisation of premium on operating lease Dividend income Finance cost Interest income Profit on sale of Investment Unrealised foreign exchange (gain) / loss (net)		1 220 /5		
Depreciation and Amortisation Expense Amortisation of premium on operating lease Dividend income Finance cost Interest income Profit on sale of Investment Unrealised foreign exchange (gain) / loss (net)		1,028.40	680.60	3,166.2
Amortisation of premium on operating lease Dividend income Finance cost Interest income Profit on sale of Investment Unrealised foreign exchange (gain) / loss (net)				
Dividend Income Finance cost Interest Income Profit on sale of Investment Unrealised foreign exchange (gain) / loss (net)		477.34	433.97	873.9
Finance cost nterest income Profit on sale of Investment Unrealised foreign exchange (gain) / loss (net)		0.77	0.77	1.5
nterest income Profit on sale of Investment Unrealised foreign exchange (gain) / loss (net)		-0.01	-	-0.0
Profit on sale of Investment Unrealised foreign exchange (gain) / loss (net)		406.04	439.75	899.0
Unrealised foreign exchange (gain) / loss (net)		-20.06	-14.50	-11.4
			-329.53	-386.8
		-79.15	18.80	181.8
Provision / write off for expected credit loss / trade receivables /		10.05	-152.50	005.5
advances (net)		-0.47		-235.5
Liabilities written back (net)		-0.47	-	
Financial guarantee Income Operating profit before wokring capital changes		2,131.96	1,077.36	4,488.6
(Increase) / Decrease in inventories		-1,031.42	-1,533.06	-243.3
Decrease / (increase) in trade receivables		736.04	417.36	-243.3
Decrease / (increase) in Loans		190.96	30.38	-2379.4
Decrease / (increase) in other financial assets			00.00	100.0
ncrease in other current / non-current assets		-448.88	567.61	857.4
ncrease / (Decrease) in trade payables		511.22	-446.03	-874
(Decrease) / Increase in provision for retirement benefits		29.87	38.77	86.1
Decrease) / Increase in other financial liabilities		-6.54	417.55	148.8
Decrease) / Increase in other current liabilities		-218.01	339.29	732.4
Effects of exchange fluctuation reserve		3.88	22.97	13.0
Cash generated from operations		1,899.08	932.20	2,929.61
Direct taxes paid (Net of refunds)		-206.73	-135.41	-388.3
Net cash flow from operating activities	(A)	1,692.35	796.79	2,541.28
		- <u></u> .		
Cash flow (used in) / from investing activities				
Purchase of fixed assets, including capital work-in-progress		-600.54	-1,829.62	-2661.4
Purchase of intangibles including Intangible assets under		-17.89	-161.29	
development				-475.8
Proceeds from sale of fixed assets		-	8.73	8.7
Decrease) / Increase in Creditors for capital goods		251.73	525.63	318.1
ncrease in Capital Advance		-340.09	-41.16	-96.2
Proceeds from Non - current investments			-	1.
Bank Balances Other than Cash and Cash Equivalents		5.70	199.19	219.0
Decrease in other financial assets		246.15	253.06	188.8
ncrease in Loans receivables		21.66		•
nterest Income		20.06	14.50	11.4
Dividend Income		0.01	-	0.0
Net cash flow used in investing activities	<u>(B)</u>	-971.39	-1,030.96	-2,485.71
Cash flow (used in) / from financing activities				45 7
Repayment of long-term borrowings (Net)		-9.74	-5.98	-15.7
Redemption of 10% Non Convertible Non Cumulative Redeemable		-858.00	-	
Preference Shares of Rs. 10 each		000.70		4000.4
Proceeds from / (Repayment) of Inter corporate deposits		-332.72	1,447.89	1398.4
Proceeds from / (Repayment) of short-term borrowings (Net)		983.44	-807.23	-619.8
Current Maturites of Long term debts			61.62 -16.85	56.9
nterest paid		-34.50 -406.04	-16.85 -439.75	21.1
Net cash flow (used in) / from financing activities	(0)	-408.04		-899.0
receasi now (used in) / from mancing activities	_(C)	-039.52	239.70	-58.12
Net increase in cash and cash equivalents			E E D	
Cash and cash equivalents at the beginning of the year / period	(A+B+C)	81.44	5.53	(2.55
Effect of exchange rate changes on Cash and cash equivalents		41.47	44.02	44.0
moor of exchange rate enanges on easil and tasil equivalents				
Cash and cash equivalents at the end of the year / Period		122.91	49.55	41.47



FOR KOPRAGE LIMITED

.

.

Surrendra Somani Executive Vice Chairman

Place : Mumbai Date : 24th October,2019

<u>ر</u> د



Website: www.kjco.net • E-mail: kjco@kjco.net

KHANDELWAL JAIN & CO. CHARTERED ACCOUNTANTS

6-B&C, Pil Court, 6th Floor, 111, M. Karve Road, Churchgate, Mumbai - 400 020. Tel.: (+91-22) 4311 5000 Fax : 4311 5050

12-B, Baldota Bhavan, 5th Floor, 117, M. Karve Road, Churchgate, Mumbai - 400 020. Tel.: (+91-22) 4311 6000 Fax: 4311 6060

Independent Auditor's Review Report on Quarterly and year to date Unaudited Standalone Financial Results of Kopran Limited Pursuant to the Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of Kopran Limited

 We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of Kopran Limited, ("the Company") for the quarter and half year ended September 30, 2019 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/CMD 1/44/2019 dated March 29, 2019 ("the Circular").

The preparation of the Statement in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder, the Circular and other accounting principles generally accepted in India is the responsibility of the Company's Management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Statement based on our review.

2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information is limited primarily to inquiries of company personnel and analytical procedures applied to financial data. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently, does not enable us to



Page 1 of 2

ĝ

「二、花、花葉を

KHANDELWAL JAIN & CO.

CHARTERED ACCOUNTANTS

obtain assurance that we would become aware of all significant matters that might be identified in an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

- 4 Attention is drawn to Note 3 of the Statement which states that the statement of cash flows for the corresponding six months period ended September 30, 2018, as reported in the accompanying Statement have been approved by the Company's Board of Directors, but have not been subjected to review.
- 3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited Standalone Financial Results, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/CMD 1/44/2019 dated March 29, 2019, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For KHANDELWAL JAIN & CO. Chartered Accountants, Firm Registration No.: 105049W

(S. S. SHAH)

PARTNER



Membership No.: 33632 UDIN : 19033632AAAABP1169

Place: Mumbai Date : October 24, 2019

Page 2 of 2

Website: www.kjco.net • E-mail: kjco@kjco.net

KHANDELWAL JAIN & CO. CHARTERED ACCOUNTANTS

6-B&C, Pil Court, 6th Floor, 111, M. Karve Road, Churchgate, Mumbai - 400 020. Tel.: (+91-22) 4311 5000 Fax : 4311 5050 12-B, Baldota Bhavan, 5th Floor, 117, M. Karve Road, Churchgate, Mumbai - 400 020. Tel.: (+91-22) 4311 6000 Fax : 4311 6060

Independent Auditor's Review Report on Quarterly and year to date Unaudited Consolidated Financial Results of Kopran Limited Pursuant to the Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of

Kopran Limited

- 1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Kopran Limited ("the Parent" or "the Company") and its subsidiaries (the parent and its subsidiaries together referred to as "the Group") for the quarter and half year ended September 30, 2019 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended read with SEBI Circular No. CIR/CFD/CMD/44/2019 dated March 29, 2019 ("the Circular").
- 2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder, the Circular and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in



Page 1 of 3

KHANDELWAL JAIN & CO.

CHARTERED ACCOUNTANTS

scope than an audit conducted in accordance with Standards on Auditing and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular issued by the Securities and Exchange Board of India under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

- 4. The Statement includes the results of the following subsidiaries:
 - Kopran Research Laboratories Limited
 - Kopran Lifesciences Limited
 - Kopran (HK) Limited
 - Kopran (UK) Limited
- 5. Attention is drawn to Note 3 of the Statement which states that the statement of cash flows for the corresponding six months period ended September 30, 2018, as reported in the accompanying Statement have been approved by the Company's Board of Directors, but have not been subjected to review.
- 6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard specified under section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
 - 6(a) We did not review the interim financial information of 2 subsidiaries included in the consolidated unaudited financial results, whose interim financial information, before consolidation adjustments, reflect total assets of Rs. 22,435.59 lakhs as at September 30, 2019, total revenues of Rs. 4,573.76 lakhs and Rs. 9,439.59 lakhs, total net profit after tax of Rs. 248.08 lakhs Rs. 444.16 lakhs and total comprehensive income of Rs.



Page 2 of 3

KHANDELWAL JAIN & CO.

CHARTERED ACCOUNTANTS

245.34 and 438.69 lakhs for the quarter and half year ended September 30, 2019, respectively, as considered in the consolidated unaudited financial results. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matter.

6(b) The consolidated unaudited financial results includes the interim financial information of 2 subsidiary which have not been reviewed by their auditors, whose interim financial information, before consolidation adjustments reflect total assets of Rs. 217.21, total revenue of Rs. NIL and Rs. 59.59 lakhs, total net profit / (loss) after tax of Rs. 1.23 lakhs and Rs. (1.02) lakhs and total comprehensive income / loss of Rs. 1.23 lakhs and (1.02) lakhs for the quarter and half year ended September 30, 2019, respectively, as considered in the consolidated unaudited financial results, based on its interim financial information which have not been reviewed by their auditors. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter.

For KHANDELWAL JAIN & CO. Chartered Accountants, Firm Registration No.: 105049W

(S. S. SHAH) MUMBA PARTNER Membership No.: 33632 UDIN: 19033632AAABQ2147 Place: Mumbai

Date : October 24, 2019

Page 3 of 3